Robert Burns
Managing Director & Senior Healthcare Analyst

Good afternoon, and welcome to the HCW BioConnect Conference. I'm Robert Burns, the Managing Director and Senior Biotech Analyst at H.C. Wainwright. And I'm joined today by David Hung and Philippe Sauvage, the CEO and CFO of Nuvation Bio, respectively. Gentlemen, thank you for joining us today.

David Hung
Founder, President, CEO & Chairman

Thanks for having us.

Philippe Sauvage
CFO & Principal Financial Officer

Thanks, Robert.

Robert Burns
Managing Director & Senior Healthcare Analyst

So for those who may be unfamiliar with Nuvation, give us a brief overview of the company and its pipeline.

David Hung
Founder, President, CEO & Chairman

So we have 3 programs right now. IBTROZI is a best-in-class ROS1 inhibitor for a type of non-small cell lung cancer. That drug was approved in July last year. We've had 3 quarters of launch, which has been very successful. We have a second asset called safusidenib. It's an IDH1 inhibitor for brain tumors. And we believe that data also will make it a best-in-class drug. That drug is in pivotal studies. And then we have a third platform, our Drug-Drug Conjugate platform which we're going to be providing an update on later this year.

Robert Burns
Managing Director & Senior Healthcare Analyst

Awesome. Yes, I can't wait to speak about the DDC platform. I'm a big fan of it. But it's coming up in almost a year since the approval of taletrectinib. And I know that you presented some updated pooled data from TRUST-I and TRUST-II. So talk to me a little